The Importance of Medication Adherence in the Treatment of Actinic Keratosis: An Expert Consensus Panel

| DOI https://doi.org/10.25251/skin.7.3.1

Page 752-763

Eruptive Keratoacanthoma in a 59-year-old Female with Chronic Kidney Disease: A Case Report and Review of Treatment Approaches

| DOI https://doi.org/10.25251/skin.7.3.2

Page 764-770

Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study)

| DOI https://doi.org/10.25251/skin.7.3.3

Page 771-787

Epidemiology and Mortality Risk Factors of Sebaceous Carcinoma: A SEER – Based Population Study

| DOI https://doi.org/10.25251/skin.7.3.4

Page 788-793

Melasma is Associated with Lower Serum Vitamin D Concentrations as Compared to Healthy Controls

| DOI https://doi.org/10.25251/skin.7.3.5

Page 794-796

The Prevalence of Secondhand Smoke Exposure in Hidradenitis Suppurativa: A Cross-Sectional Survey Study

| DOI https://doi.org/10.25251/skin.7.3.6

Page 797-801

Hidradenitis Suppurativa: A Cross-sectional Study of Content Quality on TikTok

| DOI https://doi.org/10.25251/skin.7.3.7

Page 802-806

Dermatological Findings in Children’s Films

| DOI https://doi.org/10.25251/skin.7.3.8

Page 807-810

Five Years Later: Continuing Disparity in the Geographic Density and Distribution of U.S. Dermatologists

| DOI https://doi.org/10.25251/skin.7.3.9

Page 811-816

Treatment of Severe Recalcitrant Atopic Dermatitis with Dupilumab in a Kidney Transplant Patient

| DOI https://doi.org/10.25251/skin.7.3.10

Page 817-820

Leukemia Cutis as the Presenting Sign of Acute Myeloid Leukemia in an HIV+ patient

| DOI https://doi.org/10.25251/skin.7.3.11

Page 821-823

Psoriatic Arthritis Flare in a Hospitalized Patient with Schizoaffective Disorder: A Case Report

| DOI https://doi.org/10.25251/skin.7.3.12

Page 824-828

Cutaneous Prostate Adenocarcinoma Masquerading as Cellulitis

| DOI https://doi.org/10.25251/skin.7.3.13

Page 829-833

Bazex Syndrome Associated with Angioimmunoblastic T-cell Lymphoma

| DOI https://doi.org/10.25251/skin.7.3.14

Page 834-836

A Violaceous Mass of the Chest: An Unsuspected Diagnosis of Primary Ewing Sarcoma

| DOI https://doi.org/10.25251/skin.7.3.15

Page 837-839

A Case of a Large, Painful Dermatofibrosarcoma Protuberans Arising from a Traumatic Scar

| DOI https://doi.org/10.25251/skin.7.3.16

Page 840-843

Blastomycosis-Like Pyoderma in a 59-year-old Male with Type 2 Diabetes Mellitus

| DOI https://doi.org/10.25251/skin.7.3.17

Page 844-847

Total Skin Electron Beam Therapy-Induced Erythrodermic Subacute Radiation Dermatitis in a 54-Year-Old Man with Underlying Cutaneous T-Cell Lymphoma

| DOI https://doi.org/10.25251/skin.7.3.18

Page 848-849

Disseminated Varicella-zoster Virus Infection in an Immunocompetent Host

| DOI https://doi.org/10.25251/skin.7.3.19

Page 850-851

High-grade Undifferentiated Pleomorphic Sarcoma Presenting as Acquired Lymphangioma Circumscriptum

| DOI https://doi.org/10.25251/skin.7.3.20

Page 852-853

Early Insights into the Characteristics of Tralokinumab Patients in a Real-World Setting in the United States

| DOI https://doi.org/10.25251/skin.7.supp.205

Page s205

Use of advanced systemic therapy in adolescent patients with moderate-to-severe atopic dermatitis in the TARGET-DERM Registry

| DOI https://doi.org/10.25251/skin.7.supp.206

Page s206

Unmet Needs of Adolescents with Moderate to Severe Atopic Dermatitis in the TARGET DERM Registry

| DOI https://doi.org/10.25251/skin.7.supp.207

Page s207

Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program

| DOI https://doi.org/10.25251/skin.7.supp.201

Page s201

Real-world effectiveness of ixekizumab in mild, moderate, and severe psoriasis: The patient perspective

| DOI https://doi.org/10.25251/skin.7.supp.202

Page s202

Efficacy of a Novel Formulation of Betamethasone Dipropionate 0.05% Spray Versus Augmented Betamethasone Dipropionate 0.05% Lotion In Patients >= 18 Years of Age with Moderate Plaque Psoriasis: A Pooled Analysis

| DOI https://doi.org/10.25251/skin.7.supp.203

Page s203

Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Cream for the Treatment of Plaque Psoriasis Evaluated from Pooled Phase 3 Data

| DOI https://doi.org/10.25251/skin.7.supp.204

Page s204

Impact of Actinic Keratosis on patient-reported AK symptoms, emotions and functioning measured using Skindex-16, among patients with Actinic Keratosis administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)

| DOI https://doi.org/10.25251/skin.7.supp.212

Page s212

Comparison of patient and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area, among patients with Actinic Keratosis treated with tirbanibulin in community practices across U.S.

| DOI https://doi.org/10.25251/skin.7.supp.213

Page s213

Subtype performance of the ancillary diagnostic 23- and 35-gene expression profile (GEP) tests for difficult-to-diagnose melanocytic lesions

| DOI https://doi.org/10.25251/skin.7.supp.214

Page s214

The i31-GEP for sentinel lymph node (SLN) biopsy outperforms the MSKCC nomogram in predicting the risk of having a positive SLN in patients with cutaneous melanoma

| DOI https://doi.org/10.25251/skin.7.supp.215

Page s215

The i31-gene expression profile test for cutaneous melanoma identifies patients with head and neck tumors who could forego sentinel lymph node biopsy

| DOI https://doi.org/10.25251/skin.7.supp.216

Page s216

Acne symptoms and impact of acne on social functioning, emotional functioning, and activities of daily living (ADL) among patients with moderate to severe non-nodular Acne Vulgaris (AV) in community practices across the U.S

| DOI https://doi.org/10.25251/skin.7.supp.208

Page s208

Clinician satisfaction with treatment outcomes among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication use

| DOI https://doi.org/10.25251/skin.7.supp.209

Page s209

Early and Sustained Reductions in Moderate-to-Severe Acne With Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel

| DOI https://doi.org/10.25251/skin.7.supp.210

Page s210

Benefit of Topical Combination Therapy for Acne Treatment: Analysis of Effect Size Using Number Needed to Treat

| DOI https://doi.org/10.25251/skin.7.supp.211

Page s211

Diethylene Glycol Monoethyl Ether Versus Propylene Glycol and Their Impact on Topical Clobetasol Propionate Drug Delivery

| DOI https://doi.org/10.25251/skin.7.supp.217

Page s217